ArticleJournal of diabetes and metabolic disorders2022
Use of haematological signatures in conjunction with conventional biomarkers to assess Reno-protective effects of Gedunin in diabetic nephropathy of Streptozotocin induced diabetic rats.
Article in Journal of diabetes and metabolic disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The present study was aimed at analysing the reno-protective potential of Gedunin (a limonoid from Neem leaves) through haematological and serological assays and renal histopathology studies in streptozotocin induced diabetic rats. Method: Four weeks old Wister albino rats were chosen for the study. The rats were divided into four groups of 8 rats each. Group 1 (normal control rats); Group 2 (diabetic control rats); Group 3 (Drug control rats: normal rats treated with 1 mg/kg body weight of Gedunin thrice a week through oral gavage for 2 weeks); Group 4 (diabetic rats treated with Gedunin similar to Group 3). Diabetes was induced using a single intraperitoneal injection of streptozotocin (50 mg/kg) in the pre-determined groups. After completion of treatment, the rats were sacrificed and haematological and serological parameters including functional indices of blood cells and renal markers were evaluated through spectrophotometric methods. Renal histology studies were carried out and images were captured on Olympus SC 100, 10 Mega Pixel camera. Results: Streptozotocin induced diabetes lead to marked reduction in the RBC count, haemoglobin, PCV, WBC count, lymphocyte, elevated levels of fasting blood glucose, kidney function markers such as urea, creatinine, uric acid in rats. Administration of Gedunin significantly ( Conclusion: The restoration of renal serological markers and reversal of renal tissue injuries are all indicative of promising reno-protective potential of Gedunin. Remarkable improvement of haematological parameters supports their use as reno-protection markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.